Document Detail

Enhanced spontaneous thrombolysis: a new therapeutic challenge.
MedLine Citation:
PMID:  16683213     Owner:  NLM     Status:  MEDLINE    
Spontaneous thrombolysis is an endogenous protective mechanism against lasting arterial thrombotic occlusion, which is implicated in the pathogenesis of myocardial infarction and acute coronary events. Novel therapies for coronary heart disease (CHD) targeting atherosclerosis and thrombosis, together with cardiovascular prevention programs targeting risk-factors and lifestyle provide evidence that CHD is preventable. Although reduced fibrinolytic activity is a recognized risk-factor for ischemic cardiovascular events, it has so far been neglected. Our knowledge of the fibrinolytic effect of drugs commonly used for CHD such as antiplatelet agents (aspirin, ticlopidine, clopidogrel), anti-diabetic biguanides (phenformin, metformin) or anti-hypertensive drugs is scanty and conflicting. This is mainly due to the lack of a global test of spontaneous thrombolysis, as opposed to fibrinolysis of plasma or whole blood, i.e. the assessment of various activators and inhibitors of the fibrinolytic system. A recently described technique allows the measurement of spontaneous thrombolysis, that is, lysis of an autologous platelet-rich thrombus in the absence of added plasminogen activators. Early results suggest that this test may have significant clinical potential both in identifying those at risk of fatal cardiac events and in finding new therapeutic avenues or lifestyles to improve spontaneous thrombolytic activity.
I B Kovacs; D A Gorog; J Yamamoto
Related Documents :
24786993 - Three unique presentations of atraumatic spinal cord infarction in the pediatric emerge...
2317413 - Inflammatory response, neutrophil activation, and free radical production after acute m...
17541143 - Spontaneous coronary artery dissection related to menstruation.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  21     ISSN:  0929-5305     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2006 Jun 
Date Detail:
Created Date:  2006-05-09     Completed Date:  2006-08-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  221-7     Citation Subset:  IM    
St. Bartholomew's Hospital Medical School, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Thrombosis / drug therapy,  metabolism*
Fibrinolysis / physiology
Fibrinolytic Agents / therapeutic use
Myocardial Infarction / metabolism
Reg. No./Substance:
0/Fibrinolytic Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment e...
Next Document:  Association of glycoprotein IIb/IIIa inhibitors and long-term survival following administration duri...